ACRX

AcronymDefinition
ACRXAccounting Class Data Registration Extension
References in periodicals archive ?
(Nasdaq: ACRX) is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain.
(NASDAQ: ACRX) has been notified of the acceptance of its new drug application (NDA) resubmission for Dsuvia by the US Food and Drug Administration, the company said.
He initiated coverage of AcelRx (ACRX), ANI Pharmaceuticals (ANIP), Biohaven Pharmaceutical (BHVN), Collegium Pharmaceutical (COLL), Emergent BioSolutions (EBS), Eagle Pharmaceuticals (EGRX) and Opiant Pharmaceuticals (OPNT) with Overweight ratings.
AcelRx Pharmaceuticals (ACRX), up 13% after announcing the acceptance of its New Drug Application resubmission for DSUVIA by the FDA...
(NASDAQ: ACRX) has published two studies commissioned by AcelRx to analyze errors involved with intravenous patient-controlled analgesia (IV-PCA) systems in two peer-reviewed journals, Therapeutic Advances in Drug Safety and Expert Opinion on Drug Safety, the company said.
Shares of AcelRx (ACRX) jumped at the start of trading after the drug maker, with a focus on pain management solutions, announced the successful completion of the human factors, or HF, study performed to validate the effectiveness of the revised Dsuvia directions for use in medically supervised settings.
AcelRx Pharmaceuticals (ACRX) announced the appointment of John Saia as General Counsel, effective April 16.
(NASDAQ: ACRX) has published a manuscript analysing sufentanil sublingual tablet 30 mcg for postoperative pain in the peer-reviewed journal, Pain Medicine, the company said.
(NASDAQ: ACRX) has published a manuscript titled "Sufentanil sublingual tablet 30 mcg for moderate-to-severe acute pain in the emergency department" in The American Journal of Emergency Medicine, the company said.
(NASDAQ: ACRX) has appointed Raffi Asadorian as chief financial officer, effective 16 August 2017, the company said.
(Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialisation of innovative therapies for the treatment of acute and breakthrough pain, has reported its financial results for 2013.
(NASDAQ: ACRX) said that it has received CE Mark approval (Conformite Europeenne) for the Zalviso device.